Activity Overview
This educational activity is an archive of the live presentation held on May 30, 2026.
For more information about this educational activity, the faculty,
and disclosures, please click here.
Target Audience
This
educational activity is directed toward oncologists, NPs/PAs, nurses,
pharmacists, and other HCPs involved in the management of NSCLC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Differentiate the impact of HER2 mutations, amplifications, and HER2 protein overexpression on managing advanced NSCLC
- Construct treatment plans for patients with advanced NSCLC harboring HER2 alterations based on the most up to date clinical trial safety and efficacy data
- Evaluate patient eligibility for TROP2-targeted ADCs in advanced NSCLC with and without targetable genomic alterations
- Formulate plans to mitigate adverse events associated with HER2- and TROP2-directed therapies in NSCLC
Benjamin P. Levy, MD
Associate Professor of Oncology
Johns Hopkins University School of Medicine
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Sibley Memorial Hospital
Washington, DC
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Daiichi Sankyo, Johnson & Johnson (Janssen), Merck, Pfizer
Sarah Goldberg, MD, MPH
Professor of Internal Medicine
Co-Director, Center for Thoracic Cancers
Chief, Thoracic Oncology
Yale School of Medicine
New Haven, CT
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Bayer, Daiichi Sankyo, Eli Lilly, Johnson & Johnson, Merck, Regeneron, Summit Therapeutics, Synthekine, Tubulis; Grant/Research Funding: Adela, AstraZeneca, Boehringer Ingelheim, Mirati
Jacob Sands, MD
Associate Chief, Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Assistant Professor
Harvard Medical School
Boston, MA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Fosun, Genentech, Gilead, Jazz Pharmaceuticals, Medtronic, Merck, Novartis, Pfizer, Sanofi; Grant/Research Funding: Amgen, Harpoon, Novartis
Helena Yu, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Amgen, AstraZeneca, Black Diamond, Bristol Myers Squibb, Daiichi, Janssen, Pfizer, Taiho; Grant/Research Funding (to institution): AstraZeneca, Cullinan, Daiichi, Janssen, Kumquat, Pfizer, SystImmune, Taiho
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
